Category - Developments

Developments

Hoth expands IP portfolio with filing of two patent applications

Hoth Therapeutics (NASDAQ: HOTH) has announced the filing of two U.S. provisional patent applications to expand its IP portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin...

January 5, 2026

Developments

Annovis launches OLE study in Parkinson’s disease

Annovis Bio (NYSE: ANVS) has announced it will begin an open-label extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease (PD) patients. The study aims...

December 19, 2025

Developments

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

Altimmune (NASDAQ: ALT) has announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated...

December 19, 2025

Developments

Ovid reports results of OV350 IV study

Ovid Therapeutics (NASDAQ: OVID) has announced that its Phase 1 study of OV350—the first direct activator of potassium chloride cotransporter 2 (KCC2) to be dosed in humans—administered intravenously (IV), has met its...

December 18, 2025

Developments

Tiziana doses first patient in Phase 2 trial of intranasal foralumab in AD

Tiziana Life Sciences (NASDAQ: TLSA) has announced that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease...

December 17, 2025

Developments

VYNE and Yarrow announce merger agreement

VYNE Therapeutics (NASDAQ: VYNE) has announced that it has entered into a merger agreement with closely held Yarrow Bioscience, with the combined companies expected to operate as Yarrow Bioscience under the ticker...

December 17, 2025

Developments

FDA grants fast track designation for Adagene’s muzastotug

Adagene (NASDAQ: ADAG) has announced that the FDA has designated muzastotug, in combination with Merck’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), as a fast track product for adult patients with...

December 16, 2025

Developments

RedHill’s positive opaganib results indicate reduction in venetoclax resistant cells

RedHill Biopharma (NASDAQ: RDHL) has announced positive in vivo results that indicate opaganib combined with venetoclax reduces chronic lymphocytic leukemia (CLL) cells by half compared to controls—demonstrating...

December 15, 2025

Developments

Kyverna announces positive data from trial of miv-cel in SPS

Kyverna Therapeutics (NASDAQ: KYTX) has announced positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel)—a fully human, autologous CD19-targeting CAR T-cell therapy...

December 15, 2025

Developments

Cadrenal acquires VLX-1005 for patients with HIT

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the acquisition of VLX-1005—a first-in-class, Phase 2 12-LOX inhibitor—along with additional 12-lipoxygenase (12-LOX) assets from closely held Veralox Therapeutics, for...

December 11, 2025

Category - Developments

Subscribe